(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 86-95

  Eich, Eckart ^a   Pertz, Heinz ^a   Kaloga, Macki ^a   Schulz, Jutta ^a   Fesen, Mark R ^b   Mazumder, Abhijit ^b   Pommier, Yves ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BUTANEDIOL; 2 (3,4 DIHYDROXYBENZYL) 3 (3,4 DIMETHOXYBENZYL) GAMMA BUTYROLACTONE; 2,3 BIS(3,4 DIHYDROXYBENZYL) GAMMA BUTYROLACTONE; ANTIVIRUS AGENT; ARCTIGENIN; CATECHOL; HYDROXYL GROUP; INTEGRASE; LACTONE DERIVATIVE; LIGNAN DERIVATIVE; PHENOL DERIVATIVE; TETRAHYDROFURAN; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; DNA INTEGRATION; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION;

4-BUTYROLACTONE; ANTIVIRAL AGENTS; BASE SEQUENCE; BINDING SITES; DNA NUCLEOTIDYLTRANSFERASES; ENZYME INHIBITORS; FURANS; HIV-1; HUMANS; INTEGRASES; LACTONES; LIGNANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030041593     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950387u     Document Type: Article

References (44)

1. (a) Johnson, M. I.; Hoth, D. F. Present Status and Future Prospects for HIV Therapies. Science 1993, 260, 1286-1293.
2. (b) Yarchoan, R.; Pluda, J. M.; Perno, C.-F.; Mitsuya, H.; Broder, S. Antiretroviral Therapy of Human Immunodeficiency Virus Infection: Current Strategies and Challenges for the Future. Blood 1991, 78, 859-884 (published erratum appears in Blood 1991, 78, 3330).
3. (a) Varmus, H.; Brown, P. Retroviruses. In Mobile DNA; Berg, D., Howe, M., Eds.; American Society of Microbiology: Washington, DC, 1989; pp 53-108. Goff, S. P. Genetics of Retroviral Integration. Annu. Rev. Genet. 1992, 26, 527-544.
4. (a) Varmus, H.; Brown, P. Retroviruses. In Mobile DNA; Berg, D., Howe, M., Eds.; American Society of Microbiology: Washington, DC, 1989; pp 53-108. Goff, S. P. Genetics of Retroviral Integration. Annu. Rev. Genet. 1992, 26, 527-544.
5. (c) Vink, C.; Plasterk, R. H. A. The Human Immunodeficiency Virus Integrase Protein. Trends Genet. 1993, 9, 433-437.
6. (d) Katz, R. A.; Skalka, A. M. The Retroviral Enzymes. Annu. Rev. Biochem. 1994, 63, 133-173.
7. (a) LeFemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of Active Human Immunodeficiency Virus Type 1 Integrase Enzyme for Productive Infection of Human T-Lymphoid Cells. J. Virol. 1992, 66, 7414-7419.
8. (b) Sakai, H.; Kawamura, M.; Sakuragi, J.; Sakuragi, S.; Shibata, R.; Ishimoto, A.; Ono, N.; Veda, S.; Adachi, A. Integration is Essential for Efficient Gene Expression of Human Immunodeficiency Virus Type 1. J. Virol. 1993, 67, 1169-1174.
9. Cushman, M.; Sherman, P. Inhibition of HIV-1 Integration Protein by Aurintricarboxylic Acid Monomers, Monomer Analogs, and Polymer Fractions. Biochem. Biophys. Res. Commun. 1992, 185, 85-90.
10. Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C. Inhibitory Effect of the Polyanionic Drug Suramin on the in Vitro DNA Integration Reaction. Arch. Biochem. Biophys. 1993, 305, 606-610.
11. Fesen, M. R.; Kohn, K. W.; Leteutre, F.; Pommier, Y. Inhibitors of Human Immunodeficiency Virus Integrase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2399-2403.
12. (a) Billich, A.; Schauer, M.; Frank, S.; Rosenwirth, B.; Billich, S. HIV-1 Integrase: High-Level Production and Screening Assay for the Endonucleolytic Activity. Antiviral Chem. Chemother. 1992, 3, 113-119.
13. (b) Carteau, S.; Mouscadet, J. F.; Goulaouic, H.; Subra, F.; Auclair, C. Effect of Topoisomerase Inhibitors on the in vitro HIV DNA Integration Reaction. Biochem. Biophys. Res. Commun. 1993, 192, 1409-1414.
14. Fesen, M. R.; Pommier, Y.; Leteutre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 Integrase by Flavones, Caffeic Acid Phenethyl Ester (CAPE) and Related Compounds. Biochem. Pharmacol. 1994, 48, 595-608.
15. (a) Mazumder, A.; Raghavan, K.; Weinstein, J.; Kohn, K. W.; Pommier, Y. Inhibition of Human Immunodeficiency Virus Type-1 Integrase by Curcumin. Biochem. Pharmacol. 1995, 49, 1165-1170.
16. (b) Cushman, M.; Golebiewski, W. M.; Pommier, Y.; Mazumder, A.; Reymen, D.; De Clerq, E.; Grahm, L.; Rice, W. G. Cosalane Analogs with Enhanced Potencies against HIV-1 Protease and Integrase. J. Med. Chem. 1995, 38, 443-452.
17. (c) Mazumder, A.; Gupta, M.; Perrin, D. M.; Sigman, D. S.; Rabinovitz, M.; Pommier, Y. Inhibition of Human Immunodeficiency Virus Type 1 Integrase by a Hydrophobic Cation: The Phenanthroline-Cuprous Complex. AIDS Res. Hum. Retroviruses 1995, 11, 115-125.
18. (d) Mazumder, A.; Cooney, D.; Agbaria, R.; Pommier, Y. Inhibition of Human Immunodeficiency Virus Type 1 Integrase by 3′-Azido-3′-Deozythymidylate. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 5771-5775.
19. (e) Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of Tyrphostins, Protein Kinase Inhibitors, on Human Immunodeficiency Virus Type 1 Integrase. Biochemistry 1996, in press.
20. (f) Burke, T. R.; Fesen, M. R.; Mazumder, A.; Driscoll, J.; Kohn, K.; Pommier, Y. Hydroxylated Aromatic Inhibitors of HIV-1 Integrase. J. Med. Chem. 1995, 38, 4171-4178.
21. (a) Eich, E.; Schulz, J.; Trumm, S.; Sarin, J. S.; Maidhof, A.; Merz, H.; Schroeder, H. C.; Mueller, W. E. G. Lignanolides: Novel In Vitro Anti-HIV Active Agents. Planta Med. 1990, 56, 506.
22. (b) Schroeder, H. C.; Merz, H.; Steffen, R.; Mueller, W. E. G.; Sarin, P. S.; Trumm, S.; Schulz, J.; Eich. E. Differential in Vitro Anti-HIV Activity of Natural Lignans. Z. Naturforsch. 1990, 45c, 1215-1221.
23. (a) Eich, E.; Schulz, J.; Kaloga, M.; Merz, H.; Schroeder, H. C.; Mueller, W. E. G. Interference of Epipodophyllotoxins and Natural Lignanolides with Topoisomerase II: A Proposed Molecular Mechanism. Planta Med. 1991, 57 (Suppl. 2), A7-A8.
24. (b) Pfeifer, K.; Merz, H.; Steffen, R.; Mueller, W. E. G.; Trumm, S.; Schulz, J.; Eich, E.; Schroeder, H. C. In Vitro Anti-HIV Activity of Lignans - Differential Inhibition of HIV-1 Integrase Reaction, Topoisomerase Activity and Cellular Microtubules. J. Pharm. Med. 1992, 2, 75-97.
25. Ozawa, W.; Davin, L. B.; Lewis, N. G. Formation of (-)Arctigenin in Forsythia intermedia. Phytochemistry 1993, 32, 642-602.
26. Sinha, B. K.; Politi, L. M.; Eliot, P. M.; Kerrigan, D.; Pommier, Y. Structure - Activity Relation, Cytotoxicity and Topoisomerase II Dependent Dleavage induced by Pendulum Ring Analogues of Etoposide. Eur. J. Cancer 1990, 26, 590-593.
27. MacLean, H.; Murakami, K. Lignans of Western Red Cedar (Thuja plicata). IV. Thujaplicatin and Thujaplicatin Methyl Ether. Can. J. Chem. 1966, 44, 1541-1545.
28. Henrici, A.; Kaloga, M.; Eich, E. Jacpaniculines, the First Lignanamide Alkaloids from the Convolvuaceae. Phytochemistry 1994, 37, 1637-1640.
29. Rahman, M. M. A.; Dewick, P. M.; Jackson, D. E.; Lucas, J. A. Lignans of Forsythia intermedia. Phytochemistry 1990, 29, 1971-1980.
30. Trumm, S.; Eich, E. Cytostatic Activities of Lignanolides from Ipomoea cairica. Planta Med. 1989, 55, 658-659.
31. (a) Hartwell, J. L.; Detty, W. E. Components of Podophyllin. III. Isolation of α-and β-Peltatin. Structure Studies. J. Am. Chem. Soc. 1950, 72, 246-253.
32. (b) Nadkarni, M. V.; Hartwell, J. L.; Maury, P. B.; Leiter, J. Components of Podophyllin. XI. Isolation of Two New Compounds from Podophyllum emodi Wall. J. Am. Chem. Soc. 1995, 75, 1308-1312.
33. Lange, R. G. Cleavage of Alkyl o-Hydroxyphenyl Ethers. J. Org. Chem. 1962, 27, 2037-2039.
34. Wang, Z.-Q.; Shen, Y.-C.; Chem, H.-X.; Chang, J.-Y.; Guo, X.; Cheng, Y.-C.; Lee, K.-H. Antitumor Agents 126. Novel 4β-Substituted Anilino Derivatives of 3′,4′-o,o-Didemethylpodophyllotoxin as Potent Inhibitors of Human DNA Topoisomerase II. Pharm. Res. 1993, 10, 343-350.
35. Schrecker, A. W; Hartwell, J. L. Application of Tosylate Reductions and Molecular Rotations to the Stereochemistry of Lignans. J. Am. Chem. Soc. 1955, 77, 432-437.
36. Ziegler, F. E.; Schwartz, J. A. Synthetic Studies on Lignan Lactones: Aryl Dithiane Route to (±)-Podorhizol and (±) Isopodophyllotoxone and Approaches to the Stegane Skeleton. J. Org. Chem. 1978, 43, 985-991.
37. Gonzalez, A. G.; Perez, J. P.; Trujillo, J. M. Synthesis to two Arylnaphthalene Lignans. Tetrahedon 1978, 34, 1011-1013.
38. Wiley, G. A.; Hershkowitz, R. L.; Rein, B. M.; Chung, B. C. Studies in Organophosphorus Chemistry. I. Conversion of Alcohols and Phenole to Halides by Tertiary Phosphine Dihalides. J. Am. Chem. Soc. 1964, 86, 964-965.
39. Husain, A.; Ahmad, A.; Agrawal, P. K. Chemical Studies on Phytotoxic Metabolites. Part 4. (-)-Jasmonic Acid, a Phytotoxic Substance from Botryodiplodia theobromae: Characterization by NMR Spectroscopic Methods. J. Nat. Prod. 1993, 56, 2008-2011.
40. Bushman, F. D.; Fujiwara, T.; Craigie, R. Retroviral DNA Integration Directed by HIV Integration Protein in vitro. Science 1990, 249, 1555-1558.
41. Kasper, R.; Gansser, D.; Doehmer, J. Biotransformation of the Naturally Occurring Lignan (-)-Arctigenin in Mammalian Cell Lines Genetically Engineered for Expression of Single Cytochrome P 450 Isoforms. Planta Med. 1994, 60, 441-444.
42. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; Emini, E. A.; Hazuda, D. J. Inhibition of Human Immunodeficiency Virus Integrase by Bis-Catechols. Antimicrob. Agents Chemother. 1995, 35, 320-324.
43. Chow, S. A.; Vincent, K. A.; Ellison, V.; Brown, P. O. Reversal of Integration and DNA Splicing Mediated by Integrase of Human Immunodeficiency Virus. Science 1992, 255, 723-726.
44. Bushman, F. D.; Engelman, A.; Palmer, I.; Wingfield, P.; Craigie, R. Domains of the Integrase Protein of Human Immunodeficiency Virus Type 1 Responsible for Polynucleotidyl Transfer and Zinc Binding. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3428-3432.